Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation
On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the...
Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform
Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...
GE Healthcare Launches AltiX AI.i Edition for Enhanced Cardiac Procedures
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...
Eisai Launches JPY16 Billion Tender for EcoNaviSta to Expand Dementia Care Ecosystem
Japan-based Eisai Co., Ltd (TYO: 4523) announced a tender offer valued at JPY16 billion (USD107...
Bayer’s Kerendia Gets FDA Priority Review for Heart Failure with Preserved Ejection Fraction
German pharmaceutical giant Bayer (ETR: BAYN) announced that a supplementary New Drug Application (sNDA) for...
HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...
IceCure Medical Secures Chinese Patent for Cryogenic System Connector
Israel-based IceCure Medical Ltd. (NASDAQ: ICCM) announced receiving patent authorization from the China National Intellectual...
FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development
US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...
Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio
Japan-based Taiho Pharmaceutical Co., Ltd. announced plans to fully acquire Araris Biotech AG, a Swiss...
Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational...
Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA
China-based Lifetech Scientific Corporation (HKG: 1302) announced receiving market approval from the National Medical Products...
PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...
Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...
Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...
Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...
Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...